Premium
Androgen suppression therapy and prostate cancer
Author(s) -
Oefelein Michael G.
Publication year - 2008
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.23971
Subject(s) - medicine , occult , prostate cancer , disease , prostate , coronary artery disease , oncology , cancer , carcinoma , androgen suppression , androgen , watchful waiting , gynecology , pathology , alternative medicine , hormone
Men with localized, low‐risk carcinoma of the prostate with multiple comorbidities may experience few benefits from androgen suppression therapy (AST), and probably would be better served by an active surveillance approach, with delayed AST if evidence of progression develops. A proactive position regarding the potential for AST to unmask existing or occult coronary artery disease or for AST to facilitate development of cardiovascular disease warrants consideration.